Timeline
2020
- Our company, CanBio Pharmaceuticals LLP, was formed on June 12.
2021
- We obtained our manufacturing license.
- GMP accreditation demonstrates our dedication to manufacturing quality.
- GLP accreditation ensures the quality and accuracy of chemical testing results while also
assisting in the prevention of fraud. - Started manufacturing its first Oncology product Gemcitabine Hcl.
2022
- GMP certification from WHO acknowledges our commitment to global health standards.
2023
- We developed new products, greatly extending our portfolio.
- R&D involves developing efficient and scalable synthetic approaches for large-scale API
production while retaining high purity and consistency.
2024
- Customer audit successfully completed by customers like EMCURE.
2025
- Successfully renewed WHO certificate on May 22, 2025.
- Successfully achieved ISO certificate on May 15, 2025.
- Added and commercialized 8 new molecules to the portfolio.
- Completed 3 customer audits.
Milestones
To Obtain EU-GMP Approval
Penetrate International Market
We intend to add additional molecules to our portfolio in order to present our customers with wider options.